People | February 20, 2022
Resolution Therapeutics strengthens its team with two new appointments
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage that can potentially prevent viral entry, regardless of vaccination or infection status
Fast, flexible space allows clinical trials to start when needed. A trial can become operational, pivot or scale without traditional capital building expenditures
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Subscribe To Our Newsletter & Stay Updated
